keynote-522
Published 1 year ago • 663 plays • Length 34:12Download video MP4
Download video MP3
Similar videos
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
0:50
update on keynote 522, the current standard of care for triple negative breast cancer.
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
8:05
keynote-522: immune therapy and chemotherapy in patients with early triple negative breast cancer
-
16:07
create-x
-
1:10:39
5.2.2023 multimodality conference: william a. zoghbi, md, su min chang, md, facc, & dipan j. shah...
-
7:56
young triple negative breast cancer diagnosis at 29 yo: 12 year survivor story
-
6:47
immunotherapy and the side effects
-
1:50
keynote-522 study
-
2:21
how immunotherapy might be effective for triple-negative breast cancer
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
1:56
keynote-522: optimal preoperative io and residual disease management in tnbc
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
4:17
keynote-522: efs sensitivity & subgroup analyses
-
1:29
immunotherapy keytruda shows benefit in early triple-negative breast cancer
-
0:57
a post hoc analysis of adjuvant radiation therapy in the keynote-522 study
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
8:45
keytruda phase 3 keynote-522 trial data
-
1:43
dr. rugo on the results of the keynote-522 trial in tnbc
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...